Compare Lennar Corporation (LEN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lennar Corporation vs TG Therapeutics Inc — how do they compare? Lennar Corporation trades at $85.78 (market cap $21.05B), while TG Therapeutics Inc trades at $49.69 (market cap $7.64B). The key difference: Lennar Corporation is far larger — about 2.8× TG Therapeutics Inc's market cap, and Lennar Corporation pays a 2.28% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| LEN | TGTX | |
|---|---|---|
Market Cap | $21.05B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $142.40 | $59.06 |
52-Week Low | $81.84 | $26.94 |
Enterprise Value | $24.93B | $7.84B |
Dividend Yield | 2.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lennar (LEN) trades at $85.82, showing modest daily gains of 0.26% amid mixed technical signals. The stock faces headwinds with three consecutive quarterly earnings misses and declining profitability margins, though valuation metrics remain attractive with P/E of 13.72 and P/B below 1.0. Recent news highlights institutional accumulation and dividend declarations while technical analysis indicates neutral momentum with key resistance at $88.
The outlook remains cautious as declining revenue and net income margins pressure near-term performance, though analyst consensus leans bullish with 46% buy ratings. Key risks include housing affordability challenges and elevated mortgage rates, while potential catalysts include operational efficiency improvements and market share gains in a competitive homebuilding sector.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
